30-40%
response rates
Most cancer patients do not benefit from immune checkpoint inhibitor therapy alone
The Critical Gap Upstream of Checkpoint Blockade
| ▶ | T-Cell Priming Requirement Immune checkpoint inhibitors release the brakes on the body's natural ability to kill cancer cells, but only when T cells are primed with tumor antigens. |
| ▶ | Cold Tumor Challenge "Cold" tumors, such as pancreatic, microsatellite stable colorectal, and ovarian, lack primed T cells to respond to checkpoint blockade. |
| ▶ | Tumor Antigen Expression Requirement Even when T cells are primed by antigen presentation machinery and unleashed by checkpoint blockade, they can clear tumors only if cancer cells express antigens. This requirement must be fulfilled to deliver durable responses. |
TP-317 Activates the Immune Responses Required for Checkpoint Blockade
| ▶ |
Antigen Presentation TP-317 promotes immunogenic phagocytosis of tumor debris, activating antigen presentation and T-cell priming rather than the immune silencing typical of efferocytosis. |
| ▶ |
Reduced Immune Tolerance By activating immunogenic clearance, TP-317 displaces efferocytosis that causes immune tolerance and tumor progression. |
| ▶ |
Tumor Reprogramming TP-317 reprograms tumors to present antigens — an effect confirmed by single-cell RNA analysis in multiple tumor types. This enables cytotoxic T-cells unleashed by checkpoint blockade to find and kill cancer cells. (Huang et al., 2025) |
Preclinical Results in Syngeneic Tumor Models
Added to standard of care, TP-317 reduced tumor growth by a further 58–83%
Mean ± SEM percent change in tumor volume, normalized to the untreated control of each study. Dual SOC is anti-PD-1 with cisplatin (LLC), anti-CTLA-4 (B16F10), 5-FU (CT26) or gemcitabine (KPC). Asterisks give the comparison with untreated control; brackets compare Dual SOC with Dual SOC plus TP-317.
A BLT1 antagonist abolishes the effect of TP-317
CT26, day 12. BLT1 antagonist CP-105,696 50 mg/kg; TP-317 0.3 mg/kg oral. The antagonist alone did not differ from untreated control (p = 0.72).
Two-sided Mann-Whitney U, n = 7 to 9 per group: * p < 0.05, ** p < 0.01, *** p < 0.001. Comparisons without a mark did not reach significance.
Reference
Huang S, et al. Resolvin E1 Enhances Immune Checkpoint Inhibitor Therapy by Stimulating Tumor Antigen-Presentation. Cancer Res (2025) 85 (8_Supplement_1): 6912. https://doi.org/10.1158/1538-7445.AM2025-6912
Partner with Thetis
TP-317 in oncology is available for partnering alongside the IBD program.